We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 17, 2021

High-Dose Lanreotide Autogel in Patients With Progressive Pancreatic or Midgut Neuroendocrine Tumours

European Journal of Cancer


Additional Info

European Journal of Cancer
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results
Eur. J. Cancer 2021 Nov 01;157(xx)403-414, M Pavel, JB Ćwikła, C Lombard-Bohas, I Borbath, T Shah, UF Pape, J Capdevila, F Panzuto, XM Truong Thanh, A Houchard, P Ruszniewski

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading